The HMGCL Knockout SK-HEP-1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma cell line. This loss-of-function model disrupts the HMGCL gene, which encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA lyase, a key enzyme in ketogenesis and leucine catabolism. The polyclonal format provides a heterogeneous pool of edited cells, reflecting diverse genetic backgrounds suitable for bulk metabolic studies. Through CRISPR/Cas9-mediated gene disruption, the population collectively exhibits impaired HMGCL activity, enabling researchers to investigate metabolic pathways without clonal isolation biases.
SK-HEP-1 cells are a well-characterized human liver adenocarcinoma epithelial line originally established from a patient with hepatocellular carcinoma. While they display some endothelial features, they are widely employed as a hepatocyte model for studying liver metabolism, drug toxicology, and cancer biology. Their ability to express liver-specific functions and respond to metabolic stressors makes them a relevant host for interrogating the consequences of HMGCL loss in a cancerous hepatic context. This cell line supports robust growth and is amenable to genetic manipulation, facilitating the study of metabolic enzymes like HMGCL.
HMGCL catalyzes the cleavage of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) into acetoacetate and acetyl-CoA, a pivotal reaction in ketone body production and the final step of leucine degradation. Its activity is transcriptionally regulated by PPAR?? and FOXA2 downstream of glucagon/cAMP signaling and FGF21, integrating nutrient and hormonal cues. HMGCL functions as a homodimer dependent on Mg2? or Mn2? cofactors. In ketogenesis, it acts downstream of HMGCS2 and upstream of BDH1, with acetyl-CoA also fueling the TCA cycle. Disruption of this gene disrupts the entire ketogenic pathway and alters branched-chain amino acid catabolism, linking it to broader metabolic networks.
In the SK-HEP-1 background, HMGCL knockout provides a unique platform to dissect how liver cancer cells manage energy homeostasis under nutrient deprivation. Without functional HMGCL, these cells are unable to synthesize ketone bodies, forcing reliance on alternative fuel sources such as glucose or fatty acids. This metabolic vulnerability may affect cell survival during starvation and could influence tumor progression. Since SK-HEP-1 cells partially retain hepatic characteristics, this model recapitulates features of inborn errors of ketogenesis like HMG-CoA lyase deficiency, where hypoketotic hypoglycemia and metabolic acidosis occur, making it relevant for studying disease mechanisms in a cancer microenvironment.
This product is ideally suited for metabolic disease modeling, particularly hypoketotic hypoglycemia and Reye-like syndrome, as well as for investigating ketogenesis in liver cancer metabolism. Researchers can employ ketone body measurement assays, metabolic flux analysis, and enzymatic activity assays to quantify pathway disruption. Western blotting and RT-qPCR enable confirmation of HMGCL loss, while cell viability assays under starvation conditions probe compensatory metabolic shifts. Additionally, it serves as a tool for drug toxicity screening and biomarker discovery in hepatic disorders. For further information or to discuss your specific experimental needs, please contact Ascent Research.
